

Martin Metz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4344912/publications.pdf>

Version: 2024-02-01

246
papers

16,145
citations

13865

67
h-index

20358

116
g-index

280
all docs

280
docs citations

280
times ranked

9470
citing authors

#	ARTICLE	IF	CITATIONS
1	The international EAACI/GA ² LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.	5.7	392
2	Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. <i>Nature Reviews Immunology</i> , 2022, 22, 294-308.	22.7	72
3	Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2175-2184.	5.7	26
4	Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 688-697.	2.4	15
5	Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1998-2009.e5.	2.9	26
6	Characterization of the effects on pruritus by novel treatments for atopic dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 150-156.	0.8	12
7	A Systematic Review of Aquagenic Urticaria - Subgroups and Treatment Options. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	3.8	2
8	Autoimmune chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1819-1831.	2.9	73
9	A comprehensive, tri-national, cross-sectional analysis of characteristics and impact of pruritus in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2064-2075.	2.4	8
10	Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 456-469.	2.9	70
11	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 691-700.	1.2	28
12	Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 545.	2.9	46
13	Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?. <i>Allergologie Select</i> , 2021, 5, 89-95.	3.1	10
14	Expert consensus on practical aspects in the treatment of chronic urticaria. <i>Allergo Journal International</i> , 2021, 30, 64-75.	2.0	13
15	In Chronic Spontaneous Urticaria, Comorbid Depression Linked to Higher Disease Activity, and Substance P Levels. <i>Frontiers in Psychiatry</i> , 2021, 12, 667978.	2.6	8
16	Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity. <i>Frontiers in Immunology</i> , 2021, 12, 657211.	4.8	15
17	The Diagnostic Workup in Chronic Spontaneous Urticaria – What to Test and Why. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2274-2283.	3.8	21
18	Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4797-4808.	2.4	15

#	ARTICLE	IF	CITATIONS
19	A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 506-522.e8.	2.9	29
20	Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab. <i>JAAD Case Reports</i> , 2021, 15, 36-38.	0.8	3
21	Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3810-3813.	5.7	8
22	Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 910-922.	1.2	9
23	Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00403.	1.3	20
24	Inducible Urticarias. , 2021, , 109-132.		0
25	Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1961-1969.	30.7	52
26	The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update. <i>Handbook of Experimental Pharmacology</i> , 2021, 268, 117-133.	1.8	9
27	A distinctive bullous skin reaction associated with enfortumab vedotin treatment for metastatic urothelial cancer: A case report. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1781-1783.	0.8	6
28	Pruritus and sleep disturbances in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2020, 312, 103-111.	1.9	32
29	Characterization of cowhage-induced pruritus in inflamed and non-inflamed skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 202-206.	2.4	5
30	New biological treatments for asthma and skin allergies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 546-560.	5.7	70
31	Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 318-325.e5.	3.8	93
32	Development of the Angioedema Control Test – A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1165-1177.	5.7	47
33	Effective treatment with mepolizumab in a patient with refractory Wells syndrome. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 737-739.	0.8	6
34	Flare Size but Not Intensity Reflects Histamine-Induced Itch. <i>Skin Pharmacology and Physiology</i> , 2020, 33, 244-252.	2.5	3
35	Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 38-45.	6.5	60
36	Validation of the Angioedema Control Test (AECT) – A Patient-Reported Outcome Instrument for Assessing Angioedema Control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2050-2057.e4.	3.8	50

#	ARTICLE	IF	CITATIONS
37	Management of urticarial vasculitis: A worldwide physician perspective. <i>World Allergy Organization Journal</i> , 2020, 13, 100107.	3.5	26
38	The role of eosinophils in chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1510-1516.	2.9	59
39	Mast cells and IgE in defense against lethality of venoms: Possible "benefit" of allergy. <i>Allergo Journal International</i> , 2020, 29, 46-62.	2.0	22
40	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄ...ce definicji, klasyfikacji, diagnostyki i leczenia pokrzywki. <i>Alergologia Polska - Polish Journal of Allergology</i> , 2020, 7, 1-28.	0.0	2
41	Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2373-2383.	2.4	44
42	Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1468-1475.	6.4	35
43	Ligelizumab for Chronic Spontaneous Urticaria. <i>New England Journal of Medicine</i> , 2020, 382, 579-580.	27.0	0
44	Definition, aims, and implementation of GA ² LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2115-2123.	5.7	29
45	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 321-333.	2.1	108
46	IFSI-guideline on chronic prurigo including prurigo nodularis. <i>Itch (Philadelphia, Pa)</i> , 2020, 5, e42-e42.	0.2	47
47	Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 141-151.	5.7	32
48	Treatments for chronic pruritus outside of the box. <i>Experimental Dermatology</i> , 2019, 28, 1476-1481.	2.9	8
49	Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review. <i>Acta Dermato-Venereologica</i> , 2019, 99, 905-906.	1.3	25
50	Chymase-Cre; Mcl-1fl/fl Mice Exhibit Reduced Numbers of Mucosal Mast Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2399.	4.8	9
51	Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 1171-1172.	0.8	4
52	Are we facing a change in the treatment of chronic pruritus?. <i>British Journal of Dermatology</i> , 2019, 181, 877-878.	1.5	2
53	Ligelizumab for Chronic Spontaneous Urticaria. <i>New England Journal of Medicine</i> , 2019, 381, 1321-1332.	27.0	187
54	Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20500-20504.	7.1	55

#	ARTICLE	IF	CITATIONS
55	Mast cells as protectors of health. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, S4-S18.	2.9	88
56	Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1755-1761.	2.4	7
57	Diagnosis and treatment of chronic inducible urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2550-2553.	5.7	26
58	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1793-1802.e2.	3.8	58
59	The response to treatment in chronic spontaneous urticaria depends on how it is measured. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2055-2056.e4.	3.8	9
60	Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1395-1402.	1.2	82
61	H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2043-2044.	3.8	5
62	Mast cells: Promoters of health and modulators of disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, S1-S3.	2.9	12
63	Severe contact dermatitis caused by urushiol in Japanese lacquer. <i>Contact Dermatitis</i> , 2019, 80, 55-56.	1.4	8
64	Real-life treatment of cholinergic urticaria with omalizumab. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 788-791.e8.	2.9	25
65	Position Statement: Linear prurigo is a subtype of chronic prurigo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 263-266.	2.4	24
66	Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). <i>Acta Dermato-Venereologica</i> , 2019, 99, 379-385.	1.3	40
67	Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions. <i>Acta Dermato-Venereologica</i> , 2019, 99, 1201-1209.	1.3	92
68	Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 477-478.	0.8	51
69	The EAACI/GA ² LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1393-1414.	5.7	1,008
70	Executive summary of the methods report for "The EAACI/GA ² LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update"™. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1145-1146.	5.7	74
71	The role and relevance of mast cells in urticaria. <i>Immunological Reviews</i> , 2018, 282, 232-247.	6.0	165
72	The Urticaria Activity Score"Validity, Reliability, and Responsiveness. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1185-1190.e1.	3.8	78

#	ARTICLE	IF	CITATIONS
73	Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 476-477.	0.8	1
74	Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: XACT study data. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 576-584.	5.7	51
75	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1059-1065.	2.4	150
76	Comparison and interpretability of the available urticaria activity scores. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 251-255.	5.7	50
77	Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e112-e113.	2.4	52
78	Best practices, new perspectives and the perfect emollient: optimizing the management of contact dermatitis. Journal of Dermatological Treatment, 2018, 29, 241-251.	2.2	14
79	In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema. Clinical and Experimental Dermatology, 2018, 43, 131-136.	1.3	17
80	Reply. Journal of Allergy and Clinical Immunology, 2018, 141, 1166-1167.	2.9	6
81	Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. Journal of Allergy and Clinical Immunology, 2018, 141, 638-649.	2.9	187
82	Mast cells are critical for the limitation of thrombin-induced skin inflammation. Experimental Dermatology, 2018, 27, 50-57.	2.9	11
83	Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: Results from the X-ACT study. Journal of the American Academy of Dermatology, 2018, 79, AB209.	1.2	0
84	Ein Fall von Muckle-Wells-Syndrom mit einer neuen NLRP3-Mutation. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1250-1252.	0.8	0
85	A Case of Muckle-Wells Syndrome due to novel NLRP3 mutation. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1250-1252.	0.8	2
86	Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2406-2408.	5.7	74
87	Human Mast Cell Tryptase Is a Potential Treatment for Snakebite Envenoming Across Multiple Snake Species. Frontiers in Immunology, 2018, 9, 1532.	4.8	22
88	Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant. Acta Dermato-Venereologica, 2018, 98, 26-31.	1.3	40
89	Immunoglobulin E-Mediated Autoimmunity. Frontiers in Immunology, 2018, 9, 689.	4.8	116
90	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2073-2075.	5.7	22

#	ARTICLE	IF	CITATIONS
91	Looking forward to new targeted treatments for chronic spontaneous urticaria. Clinical and Translational Allergy, 2017, 7, 1.	3.2	57
92	Membrane-bound stem cell factor is the major but not only driver of fibroblast-induced murine skin mast cell differentiation. Experimental Dermatology, 2017, 26, 255-262.	2.9	18
93	Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1440-1460.	5.7	124
94	Responsiveness and minimal important difference of the urticaria control test. Journal of Allergy and Clinical Immunology, 2017, 140, 1710-1713.e11.	2.9	68
95	Omalizumab is effective in symptomatic dermatographism—results of a randomized placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 870-873.e5.	2.9	73
96	Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 864-867.e5.	2.9	92
97	Potential blood biomarkers in chronic spontaneous urticaria. Clinical and Experimental Allergy, 2017, 47, 19-36.	2.9	76
98	041 Prevalence, characteristics and burden of pruritus in chronic dermatoses. Journal of Investigative Dermatology, 2017, 137, S199.	0.7	0
99	057 The role of substance P and its receptor NK1R in chronic prurigo: Results from a randomized, controlled trial with topical aprepitant. Journal of Investigative Dermatology, 2017, 137, S202.	0.7	0
100	S2k Guidelines for the diagnosis and treatment of chronic pruritus — update — short version. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-872.	0.8	23
101	S2k Leitlinie zur Diagnostik und Therapie des chronischen Pruritus — Update — Kurzversion. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-873.	0.8	56
102	Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2017, 139, 1059-1061.e1.	2.9	167
103	Autoimmune chronic spontaneous urticaria: What we know and what we do not know. Journal of Allergy and Clinical Immunology, 2017, 139, 1772-1781.e1.	2.9	240
104	Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. Journal of Allergy and Clinical Immunology, 2017, 139, 1311-1320.	2.9	89
105	Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcÎµRI-positive cells in the skin. Theranostics, 2017, 7, 1266-1276.	10.0	113
106	Development and Validation of a Questionnaire for the Assessment of Pelvic Floor Disorders and Their Risk Factors During Pregnancy and Post Partum. Geburtshilfe Und Frauenheilkunde, 2017, 77, 358-365.	1.8	29
107	Effect of omalizumab on angioedema in H ₁ -antihistamine-resistant chronic spontaneous urticaria patients: results from XACT, a randomized controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1135-1144.	5.7	108
108	Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1357-1361.	2.4	11

#	ARTICLE	IF	CITATIONS
109	Definition, aims, and implementation of ² GA² LEN Urticaria Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1210-1218.	5.7	110
110	Omalizumab normalizes gene expression in lesional skin of patients with chronic spontaneous urticaria: Results from a randomized, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology, 2016, 74, AB64.	1.2	0
111	Skin provocation tests may help to diagnose atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1745-1752.	5.7	17
112	The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA² LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 780-802.	5.7	268
113	Poster Discussion Session PDS. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 118-272.	5.7	11
114	Itch Management: Topical Agents. Current Problems in Dermatology, 2016, 50, 40-45.	0.7	11
115	A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2016, 138, 1730-1732.	2.9	60
116	Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure. Journal of Immunology, 2016, 197, 4240-4246.	0.8	50
117	Mastzellen und Basophile. , 2016, , 69-75.		0
118	Galactose-1,3-Galactose Allergy Is Not a Hitherto Unrecognized Cause of Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology, 2015, 167, 250-252.	2.1	10
119	Effectiveness of canakinumab treatment in Schnitzler's syndrome: a multi-center randomized placebo-controlled study. Pediatric Rheumatology, 2015, 13, .	2.1	4
120	The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Przegląd Dermatologiczny, 2015, 2, 155-179.	0.1	11
121	Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial. Dermatology and Therapy, 2015, 5, 217-230.	3.0	9
122	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄ...ce definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami. Alergologia Polska - Polish Journal of Allergology, 2015, 2, T1-T23.	0.0	0
123	Omalizumab may not inhibit mast cell and basophil activation <i>in vitro</i>. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1832-1836.	2.4	16
124	The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2015, 135, 337-342.e2.	2.9	208
125	Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability. Acta Dermato-Venereologica, 2014, 96, 792-6.	1.3	5
126	Polidocanol inhibits cowhage -but not histamine-induced itch in humans. Experimental Dermatology, 2014, 23, 922-923.	2.9	28

#	ARTICLE	IF	CITATIONS
127	Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 113-117.	5.7	108
128	Mast cells protect from skin tumor development and limit tumor growth during cutaneous <i>de novo</i> carcinogenesis in a K ⁺ it ⁺ -dependent mouse model. <i>Experimental Dermatology</i> , 2014, 23, 159-164.	2.9	27
129	Retreatment With Omalizumab Results in Rapid Remission in Chronic Spontaneous and Inducible Urticaria. <i>JAMA Dermatology</i> , 2014, 150, 288.	4.1	123
130	Omaliuzumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. <i>Journal of Dermatological Science</i> , 2014, 73, 57-62.	1.9	222
131	Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1365-1372.e6.	2.9	268
132	The EAACI/GA ² LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 868-887.	5.7	912
133	A novel method to generate and culture human mast cells: Peripheral CD34 ⁺ stem cell-derived mast cells (PSCMCs). <i>Journal of Immunological Methods</i> , 2014, 413, 62-68.	1.4	37
134	Methods report on the development of the 2013 revision and update of the EAACI/GA ² LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, e1-29.	5.7	75
135	Substance P Is Upregulated in the Serum of Patients with Chronic Spontaneous Urticaria. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2833-2836.	0.7	61
136	Type 2 Immunity Can Have a Protective Role In Host Defense Against Venoms In Mice. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB90.	2.9	0
137	Development of a standardized experimental itch model in humans. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, AB42.	1.2	1
138	IgE Antibodies and Fc γ RI Are Critical For Acquired Resistance Against Honeybee Venom In Mice. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB225.	2.9	0
139	Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. <i>Neurobiology of Disease</i> , 2014, 62, 260-272.	4.4	50
140	Mast Cell-Mediated Reactions In Vivo. <i>Methods in Molecular Biology</i> , 2014, 1192, 239-247.	0.9	3
141	Oral Allergy Syndrome. , 2014, , 37-50.		0
142	The effects of <i>Fasciola hepatica</i> tegumental antigens on mast cell function. <i>International Journal for Parasitology</i> , 2013, 43, 531-539.	3.1	16
143	A Beneficial Role for Immunoglobulin E in Host Defense against Honeybee Venom. <i>Immunity</i> , 2013, 39, 963-975.	14.3	151
144	Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 751-754.e5.	2.9	52

#	ARTICLE	IF	CITATIONS
145	Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. JDDG - Journal of the German Society of Dermatology, 2013, 11, 971-978.	0.8	39
146	Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, Neopterin, and VEGF are not elevated in chronic spontaneous urticaria. Journal of Dermatological Science, 2013, 70, 222-225.	1.9	29
147	Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1049-1055.	0.8	6
148	Miltefosine: a novel treatment option for mast cell-mediated diseases. Journal of Dermatological Treatment, 2013, 24, 244-249.	2.2	10
149	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet, The, 2013, 382, 1380.	13.7	35
150	Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 949-952.	5.7	46
151	Chronic pruritus associated with dermatologic disease in infancy and childhood: Update from an interdisciplinary group of dermatologists and pediatricians. Pediatric Allergy and Immunology, 2013, 24, 527-539.	2.6	26
152	Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4. FASEB Journal, 2013, 27, 920-929.	0.5	48
153	<i>Fasciola hepatica</i> Tegumental Coat Impairs Mast Cells' Ability To Drive Th1 Immune Responses. Journal of Immunology, 2013, 190, 2873-2879.	0.8	49
154	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 816-819.	5.7	53
155	Magistralrezeptur und Pruritus therapie - Was ist etabliert, was hat sich bewährt, was ist neu?. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1049-1056.	0.8	12
156	Neues von der internationalen Leitlinie für Diagnostik und Therapie der chronischen Urtikaria. JDDG - Journal of the German Society of Dermatology, 2013, 11, 971-979.	0.8	26
157	German Version of ItchyQoL: Validation and Initial Clinical Findings. Acta Dermato-Venereologica, 2013, 93, 562-568.	1.3	53
158	Effective Control of Recalcitrant Pruritus by Bevacizumab: A Possible Role for Vascular Endothelial Growth Factor in Chronic Itch?. Acta Dermato-Venereologica, 2013, 93, 175-179.	1.3	17
159	Development, validation, and initial results of the Angioedema Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1185-1192.	5.7	147
160	Mast cells rescue implantation defects caused by c-kit deficiency. Cell Death and Disease, 2013, 4, e462-e462.	6.3	74
161	Palliative treatment of skin metastases in dermatocarcinoma. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1041-1046.	0.8	13
162	Protocols for the Induction and Evaluation of Systemic Anaphylaxis in Mice. Methods in Molecular Biology, 2013, 1032, 133-138.	0.9	17

#	ARTICLE	IF	CITATIONS
163	Mast cells, basophils, and mastocytosis. , 2013, , 284-297.		3
164	Pathomechanismus von Angio�demem. Allergologie, 2013, 36, 85-91.	0.1	1
165	Neue Therapeutika beim Heredit�ren Angio�dem � unbeantwortete Fragen beim Heredit�ren Angio�dem. Allergologie, 2013, 36, 120-127.	0.1	0
166	Omalizumab in chronic urticaria. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 406-411.	2.3	48
167	The role of interleukin-1 in allergy-related disorders. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 477-484.	2.3	73
168	Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6644-6649.	7.1	145
169	Role and Relevance of Mast Cells in Fungal Infections. Frontiers in Immunology, 2012, 3, 146.	4.8	54
170	Development and construct validation of the angioedema quality of life questionnaire. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1289-1298.	5.7	182
171	Atopic dermatitis in children: management of pruritus. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 2-8.	2.4	43
172	Mast cells cultured from IL-3-treated mice show impaired responses to bacterial antigen stimulation. Inflammation Research, 2012, 61, 79-85.	4.0	16
173	Evidence that the endothelin A�receptor can enhance IgE-dependent anaphylaxis in mice. Journal of Allergy and Clinical Immunology, 2011, 128, 424-426.e1.	2.9	11
174	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133
175	Pathophysiology of itch and new treatments. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 420-427.	2.3	66
176	Pruritus: an overview of current concepts. Veterinary Dermatology, 2011, 22, 121-131.	1.2	41
177	Treatment of notalgia paraesthetica with an 8% capsaicin patch. British Journal of Dermatology, 2011, 165, 1359-1361.	1.5	18
178	Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Review of Clinical Immunology, 2011, 7, 15-20.	3.0	23
179	Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. Archives of Dermatology, 2011, 147, 1221.	1.4	22
180	High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Dermato-Venereologica, 2011, 91, 557-561.	1.3	110

#	ARTICLE	IF	CITATIONS
181	IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria?. PLoS ONE, 2011, 6, e14794.	2.5	216
182	Effects of Antihistamines on Innate Immune Responses to Severe Bacterial Infection in Mice. International Archives of Allergy and Immunology, 2011, 155, 355-360.	2.1	17
183	Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. Journal of Clinical Investigation, 2011, 121, 4180-4191.	8.2	134
184	IL-9 Production by Regulatory T Cells Recruits Mast Cells That Are Essential for Regulatory T Cell-Induced Immune Suppression. Journal of Immunology, 2011, 186, 83-91.	0.8	160
185	Evidence for Non-Allergic Mast Cell Activation in Pollen-Associated Inflammation. Journal of Investigative Dermatology, 2011, 131, 987-990.	0.7	6
186	T cell killing by tolerogenic dendritic cells protects mice from allergy. Journal of Clinical Investigation, 2011, 121, 3860-3871.	8.2	31
187	Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	5
188	Chronic pruritus – pathogenesis, clinical aspects and treatment. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1249-1260.	2.4	62
189	Erfolgreiche Behandlung des hereditären Angioödems mit dem Bradykinin-B2-Rezeptor-Antagonisten icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	7
190	Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
191	Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2010, 126, 665-666.	2.9	59
192	Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Annals of Allergy, Asthma and Immunology, 2010, 104, 86-92.	1.0	62
193	Standard Operating Procedures: A Practical Approach. , 2010, , 141-151.		0
194	Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clinical and Experimental Dermatology, 2009, 34, e137-e140.	1.3	21
195	Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. Experimental Dermatology, 2009, 18, 160-166.	2.9	22
196	Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Experimental Dermatology, 2009, 18, 437-444.	2.9	91
197	Patients with chronic urticaria exhibit increased rates of sensitisation to <i>Candida albicans</i> , but not to common moulds. Mycoses, 2009, 52, 334-338.	4.0	25
198	Differential effects of skin nerves on allergic skin inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 496-497.	5.7	2

#	ARTICLE	IF	CITATIONS
199	The definition and diagnostic testing of physical and cholinergic urticarias â€“ EAACI/GA ² /LEN/EDF/UNEV consensus panel recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1715-1721.	5.7	143
200	Innate immunity and allergy in the skin. <i>Current Opinion in Immunology</i> , 2009, 21, 687-693.	5.5	57
201	Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 705-706.	2.9	67
202	Prevalence and relevance of skin autoreactivity in chronic urticaria. <i>Expert Review of Dermatology</i> , 2009, 4, 655-663.	0.3	3
203	Mast cells: makers and breakers of allergic inflammation. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 427-430.	2.3	52
204	Nonâ€“pathogenic commensal <i>Escherichia coli</i> bacteria can inhibit degranulation of mast cells. <i>Experimental Dermatology</i> , 2008, 17, 427-435.	2.9	47
205	Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. <i>Nature Medicine</i> , 2008, 14, 392-398.	30.7	114
206	Successful treatment of cholinergic urticaria with antiâ€“immunoglobulin E therapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 247-249.	5.7	112
207	Successful treatment of solar urticaria with antiâ€“immunoglobulin E therapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1563-1565.	5.7	149
208	Mast cellâ€“driven skin inflammation is impaired in the absence of sensory nerves. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 955-961.	2.9	75
209	Mast cell functions in the innate skin immune system. <i>Immunobiology</i> , 2008, 213, 251-260.	1.9	104
210	Mast cells, basophils and mastocytosis. , 2008, , 345-360.		0
211	Mast cells â€“ key effector cells in immune responses. <i>Trends in Immunology</i> , 2007, 28, 234-241.	6.8	264
212	Control of <i>Pseudomonas aeruginosa</i> Skin Infections in Mice Is Mast Cell-Dependent. <i>American Journal of Pathology</i> , 2007, 170, 1910-1916.	3.8	80
213	IL-15 constrains mast cellâ€“dependent antibacterial defenses by suppressing chymase activities. <i>Nature Medicine</i> , 2007, 13, 927-934.	30.7	102
214	Acquired cold urticaria symptoms can be safely prevented by ebastine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1465-1468.	5.7	38
215	Mast cells in the promotion and limitation of chronic inflammation. <i>Immunological Reviews</i> , 2007, 217, 304-328.	6.0	275
216	Inflammatory Murine Skin Responses to UV-B Light Are Partially Dependent on Endothelin-1 and Mast Cells. <i>American Journal of Pathology</i> , 2006, 169, 815-822.	3.8	51

#	ARTICLE	IF	CITATIONS
217	Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial. <i>Dermatology</i> , 2006, 212, 150-159.	2.1	120
218	Mast Cells Can Enhance Resistance to Snake and Honeybee Venoms. <i>Science</i> , 2006, 313, 526-530.	12.6	333
219	Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?. <i>Experimental Dermatology</i> , 2006, 15, 913-916.	2.9	54
220	Viewpoint 5. <i>Experimental Dermatology</i> , 2006, 15, 924-925.	2.9	0
221	Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. <i>British Journal of Dermatology</i> , 2006, 154, 294-298.	1.5	189
222	Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. <i>Current Opinion in Immunology</i> , 2006, 18, 751-760.	5.5	100
223	Skin mast cells control T cell-dependent host defense in <i>Leishmania major</i> infections. <i>FASEB Journal</i> , 2006, 20, 2460-2467.	0.5	123
224	Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?. <i>Experimental Dermatology</i> , 2006, 15, 913-929.	2.9	23
225	The <i>status quo</i> and <i>quo vadis</i> of mast cells. <i>Experimental Dermatology</i> , 2005, 14, 923-929.	2.9	51
226	TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. <i>Blood</i> , 2005, 106, 978-987.	1.4	157
227	Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. <i>Experimental Dermatology</i> , 2004, 13, 273-281.	2.9	29
228	Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. <i>Nature</i> , 2004, 432, 512-516.	27.8	275
229	Peltier effect-based temperature challenge: An improved method for diagnosing cold urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1224-1225.	2.9	63
230	What is the physiological function of mast cells?. <i>Experimental Dermatology</i> , 2003, 12, 886-886.	2.9	187
231	Viewpoint 1. <i>Experimental Dermatology</i> , 2003, 12, 887-891.	2.9	0
232	Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1 α released from neutrophils recruited by mast cell-derived TNF α . <i>Blood</i> , 2003, 101, 210-215.	1.4	130
233	Critical role of IL-10 in the induction of low zone tolerance to contact allergens. <i>Journal of Clinical Investigation</i> , 2003, 112, 432-439.	8.2	40
234	A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 479-485.	3.7	71

#	ARTICLE	IF	CITATIONS
235	A Role for Bax in the Regulation of Apoptosis in Mouse Mast Cells. <i>Journal of Investigative Dermatology</i> , 2000, 114, 1205-1206.	0.7	26
236	Distinct Roles for Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Controlling the Rate of Hair Follicle Morphogenesis. <i>Journal of Investigative Dermatology</i> , 2000, 114, 314-320.	0.7	32
237	Control of murine hair follicle regression (catagen) by TGF β 1 <i>in vivo</i> . <i>FASEB Journal</i> , 2000, 14, 752-760.	0.5	301
238	A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in hair cycle control. <i>FASEB Journal</i> , 1999, 13, 395-410.	0.5	93
239	Retardation of Hair Follicle Development by the Deletion of TrkC, High-Affinity Neurotrophin-3 Receptor. <i>Journal of Investigative Dermatology</i> , 1999, 113, 425-427.	0.7	13
240	Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act as "epitheliotrophins" in murine skin. <i>Laboratory Investigation</i> , 1999, 79, 557-72.	3.7	22
241	A New Role for Neurotrophin-3. <i>American Journal of Pathology</i> , 1998, 153, 785-799.	3.8	81
242	New roles for neurotrophin-3, neurotrophin-4 and brain-derived neurotrophic factor: Involvement in hair growth control. <i>Journal of Dermatological Science</i> , 1998, 16, S9.	1.9	0
243	Modulation of skin mast cell functions in situ by neurotrophin-3. <i>Journal of Dermatological Science</i> , 1998, 16, S165.	1.9	0
244	Anpassung der Therapiekonzepte: Chronische spontane Urtikaria – eine Autoimmunkrankheit. , 0, , .		0
245	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	51
246	STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2